Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 141, Issue 3, Pages 479-486Publisher
SPRINGER
DOI: 10.1007/s11060-019-03098-y
Keywords
5-ALA; FDA; Optical imaging; Glioblastoma; High-grade gliomas; Intraoperative imaging; Brain tumors; Gliomas
Categories
Funding
- NCI NIH HHS [R01 CA176659] Funding Source: Medline
Ask authors/readers for more resources
The US Food and Drug Administration (FDA) approved 5-aminolevulinic acid (5-ALA; Gleolan((R)); photonamic GmbH and Co. KG) for use as an intraoperative optical imaging agent in patients with suspected high-grade gliomas (HGGs) in 2017. This was the first ever optical imaging agent approved as an adjunct for the visualization of malignant tissue during surgery for brain tumors. The approval occurred a decade after European approval and a multicenter, phase III randomized trial which confirmed that surgeons using 5-ALA fluorescence-guided surgery as a surgical adjunct could achieve more complete resections of tumors in HGG patients and better patient outcomes than with conventional microsurgery. Much of the delay in the US FDA approval of 5-ALA stemmed from its conceptualization as a therapeutic and not as an intraoperative imaging tool. We chronicle the challenges encountered during the US FDA approval process to highlight a new standard for approval of intraoperative optical imaging agents in brain tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available